GlassScriptPhysician profile
Veleka Mayfield
NPI 1750001921
$7,838.49
in general payments reported to CMS, 2019-2025
27 companies · $2,769 in 2025
The $2,769 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $291 · 2023: $1,760 · 2024: $2,894 · 2025: $2,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,112 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,112.37 |
| Education | $310.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,684.88 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,535.93 | 2023-2025 | |
| Novo Nordisk INC | $1,386.38 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $530.77 | 2023-2025 | |
| Astellas Pharma US INC | $382.07 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.56 | 2023-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $309.04 | 2025 | Caplyta |
| Lilly USA, LLC | $281.31 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $253.47 | 2023-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $234.88 | 2023 | Xarelto |
| Sanofi Pasteur INC. | $160.05 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $129.58 | 2023-2024 | Verquvo, Gardasil, Vaxneuvance |
| Phathom Pharmaceuticals, INC. | $113.80 | 2025 | Voquezna |
| Exact Sciences Corporation | $69.68 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $57.27 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $53.86 | 2024 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $51.67 | 2024 | |
| Dexcom, INC. | $48.48 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $45.91 | 2022-2024 | Nexplanon |
| Seqirus USA INC | $42.84 | 2023-2024 | Fluad Quadrivalent, Flucelvax Quadrivalent, Fluad |
| Hologic Sales and Service, LLC | $23.77 | 2025 | Aptima, Thinprep 2000 Processor |
| Xeris Pharmaceuticals, INC. | $21.36 | 2023 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $21.09 | 2024 | |
| Shield Therapeutics INC | $19.02 | 2025 | |
| Hikma Pharmaceuticals USA | $18.99 | 2024 | Ryaltris |
| Corcept Therapeutics | $15.92 | 2024 | Korlym |
| Mylan Pharmaceuticals INC. | $14.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veleka Mayfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.